{"id":"https://openalex.org/W2463965415","doi":null,"title":"[Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].","display_name":"[Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)].","publication_year":2014,"publication_date":"2014-10-01","ids":{"openalex":"https://openalex.org/W2463965415","mag":"2463965415","pmid":"https://pubmed.ncbi.nlm.nih.gov/25335703"},"language":"ja","primary_location":{"id":"pmid:25335703","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25335703","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"English Abstract"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5114888565","display_name":"Yutaka Yamamoto","orcid":"https://orcid.org/0000-0002-7555-6295","observed_orcids":["https://orcid.org/0000-0002-7555-6295"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yutaka Yamamoto","raw_affiliation_strings":["Kumamoto Breast Cancer Cooperative Group: KBCCG"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kumamoto Breast Cancer Cooperative Group: KBCCG","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024576654","display_name":"Reiki Nishimura","orcid":"https://orcid.org/0000-0003-0645-7880","observed_orcids":["https://orcid.org/0000-0003-0645-7880"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Reiki Nishimura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108925745","display_name":"Tomio TANIGAWA","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tomio Tanigawa","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055243268","display_name":"Ichiro Kawano","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ichiro Kawano","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Kyoji Hayashi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kyoji Hayashi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111406458","display_name":"Masafumi Kuramoto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Masafumi Kuramoto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087891477","display_name":"Mutsuko Yamamoto\u2010Ibusuki","orcid":"https://orcid.org/0000-0002-3529-9706","observed_orcids":["https://orcid.org/0000-0002-3529-9706"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mutsuko Yamamoto-Ibusuki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5035071748","display_name":"Hirotaka Iwase","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hirotaka Iwase","raw_affiliation_strings":["Faculty of Life Science (Medical Sciences/Clinical research), Research and Education Center for Metabolic Abnormality and Cancer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Faculty of Life Science (Medical Sciences/Clinical research), Research and Education Center for Metabolic Abnormality and Cancer","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1637,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.52384011,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"41","issue":"10","first_page":"1221","last_page":"5"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.41530001163482666,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.41530001163482666,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.40720000863075256,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.06469999998807907,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ts-1","display_name":"TS-1","score":0.8999999761581421},{"id":"https://openalex.org/keywords/fluoropyrimidine","display_name":"fluoropyrimidine","score":0.7450000047683716},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8669999837875366},{"id":"https://openalex.org/keywords/breast-cancer-recurrence","display_name":"breast cancer recurrence","score":0.9089999794960022},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.8500000238418579},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.8050000071525574},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.7919999957084656},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7889999747276306},{"id":"https://openalex.org/keywords/creatinine-clearance","display_name":"creatinine clearance","score":0.875},{"id":"https://openalex.org/keywords/renal-function","display_name":"renal function","score":0.6119999885559082},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.5590000152587891}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.863141655921936},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.8121989369392395},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.7960468530654907},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6942628026008606},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.6903077363967896},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.6896206140518188},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6795552968978882},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.6399160623550415}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005641","descriptor_name":"Tegafur","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005641","descriptor_name":"Tegafur","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010094","descriptor_name":"Oxonic Acid","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010094","descriptor_name":"Oxonic Acid","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:25335703","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25335703","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"English Abstract"},{"id":"mag:2463965415","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25335703","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2198777003","https://openalex.org/W2364281819","https://openalex.org/W2269432776","https://openalex.org/W2559774347","https://openalex.org/W2960106991","https://openalex.org/W2418300745","https://openalex.org/W2465255305","https://openalex.org/W2994544895","https://openalex.org/W2407030491","https://openalex.org/W197783315"],"abstract_inverted_index":{"TS-1,":[0],"an":[1,24],"oral":[2],"fluoropyrimidine,":[3],"is":[4],"known":[5],"to":[6,48,122,137],"be":[7,111,135],"effective":[8],"for":[9,117],"the":[10,28,127],"treatment":[11,116],"of":[12,32,75,85,100,129],"various":[13],"carcinomas":[14],"including":[15],"advanced/metastatic":[16,118],"breast":[17,44,119],"cancer.The":[18,45],"Kumamoto":[19],"Breast":[20],"Cancer":[21],"Cooperative":[22],"Group(KBCCG)conducted":[23],"observational":[25],"study,":[26],"wherein,":[27],"efficacy":[29],"and":[30,59,72,89,94,125],"safety":[31,124],"TS-1":[33,107,132],"monotherapy":[34,108],"was":[35,51,57,63,95],"analyzed":[36],"in":[37,69,80],"35":[38],"patients":[39],"with":[40,97],"recurrent":[41],"or":[42],"metastatic":[43],"median":[46],"time":[47],"cancer":[49,120],"progression":[50],"3.7":[52],"months,":[53],"overall":[54],"response":[55],"rate":[56,62,84],"12%,":[58],"clinical":[60],"benefit":[61],"32%.":[64],"Adverse":[65],"events":[66,74,92],"were":[67,78],"observed":[68,79],"27":[70],"patients(77%),":[71],"adverse":[73,91,140],"Grade":[76,87],">3":[77],"7":[81],"patients(20%).":[82],"The":[83],"treatment-related":[86],"3":[88],"4":[90],"increased,":[93],"associated":[96],"poor":[98],"levels":[99],"creatinine":[101],"clearance(Ccr)ie":[102],"<60mL/min.This":[103],"study":[104],"suggests":[105],"that":[106],"can":[109],"potentially":[110],"used":[112],"as":[113],"a":[114],"salvage":[115],"owing":[121],"its":[123],"efficacy.Measuring":[126],"level":[128],"Ccr":[130],"before":[131],"therapy":[133],"should":[134],"considered":[136],"avoid":[138],"severe":[139],"events.":[141]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2015,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2016-07-22T00:00:00"}